-
Product Insights
New![]()
Net Present Value Model: DiaMedica Therapeutics Inc’s DM-199
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DM-199 in Diabetic Nephropathy
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DM-199 in Diabetic Nephropathy Drug Details: DM-199 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DM-5167 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DM-5167 in Solid Tumor Drug Details: DM-5167 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DM-199 in Vascular Dementias
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DM-199 in Vascular Dementias Drug Details: DM-199 is under development for the treatment of diabetic...
-
Company Insights
New![]()
Innovation and Patenting activity of Mitsui DM Sugar Holdings Co Ltd Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Mitsui DM Sugar Holdings Co Ltd Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DM-199 in Acute Ischemic Stroke
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DM-199 in Acute Ischemic Stroke Drug Details: DM-199 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DM-199 in IgA Nephropathy (Berger’s Disease)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DM-199 in IgA Nephropathy (Berger's Disease) Drug Details: DM-199 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DM-199 in Chronic Kidney Disease (Chronic Renal Failure)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DM-199 in Chronic Kidney Disease (Chronic Renal Failure) Drug Details: DM-199 is under development for...
-
Sector Analysis
New![]()
Hungary Retail Market Size by Sector and Channel Including Online Retail, Key Players and Forecast to 2027
Hungary Retail Market Report Overview The Hungary retail market size was HUF 14,289 billion in 2022. The market is expected to grow at a CAGR of more than 7% during 2022-2027. The Hungary retail market research report provides both historic and forecast market data for total retail sales in Hungary. Hungary Retail Market Outlook, 2022 - 2027 (HUF Billion) Buy Full Report for More Insights into the Hungary Retail Market Forecast Download A Free Report Sample The report illustrates the...
-
Sector Analysis
New![]()
Slovak Republic Retail Market Size by Sector and Channel Including Online Retail, Key Players and Forecast to 2027
Slovak Republic Retail Market Report Overview The Slovak Republic retail market size was EUR 31.7 billion in 2022. The market is expected to grow at a CAGR of more than 4% during 2022-2027. The Slovak Republic retail market research report provides both historic and forecast market data for total retail sales in the Slovak Republic. Slovak Republic Retail Market Outlook, 2022 - 2027 (EUR Billion) Buy Full Report for More Insights into the Slovak Republic Retail Market Forecast Download A...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.